Annual report 2022

— Corporate governance — Corporate structure and shareholders

Corporate structure and shareholders

medmix Ltd is subject to the laws of Switzerland, in particular Swiss corporate and stock exchange laws. The company also applies the Swiss Code of Best Practice for Corporate Governance. medmix Ltd has a single share class and has separated the functions of Chairman of the Board of Directors and CEO. The information in the following section is set out in the order defined by the SIX Swiss Exchange directive on information relating to corporate governance (RLCG), with subsections summarized as far as possible. medmix Ltd’s consolidated financial statements comply with International Financial Reporting Standards (IFRS), and, in certain sections, readers are referred to the financial reporting section in the medmix annual report 2022. medmix Ltd reports the compensation of the Board of Directors and the Executive Committee in the compensation report. Unless otherwise indicated, the following information refers to the situation on December 31, 2022. Accordingly, the corporate governance report does not reflect the revised corporate law, in force as of January 1, 2023. The Board of Directors intends to propose to the Shareholder's Meeting in April 2023 the revision of the current Articles of Association. Shareholders will receive a report from the Board of Directors explaining the proposed amendments ahead of the Shareholder's Meeting. Further information on corporate governance is published on

Corporate structure

The group is organized into two business areas, Healthcare and Consumer & Industrial, and the organizational group structure corresponds to these reported business areas. More information on this operational corporate structure can be found under note 3 to the consolidated financial statements in the financial reporting section. medmix Ltd is the only medmix group company listed on a stock exchange. It is based in Baar, Switzerland. Its shares are listed and traded on the SIX Swiss Exchange in Zurich (Securities no. 112.967.710/ISIN CH1129677105). On December 31, 2022, the market capitalization of all issued shares of medmix Ltd was CHF 726,217,712. Information on the subsidiaries included in the consolidation can be found under note 33 to the consolidated financial statements. The list comprises all consolidated direct subsidiaries of medmix Ltd and all further consolidated subsidiaries.

Significant shareholders

According to notifications received from medmix Ltd shareholders, several shareholders held more than 3% of medmix Ltd’s share capital on December 31, 2022. As published on the SIX disclosure platform on October 8, 2021, Viktor F. Vekselberg held 40.54% of medmix' shares. The shares are directly held by Tiwel Holding AG. On October 5, 2021, The Capital Group Companies, Inc. held 5.01% of medmix' shares, while FIL Limited held 4.90%, as published on November 17, 2021. As published on October 8, 2021, UBS Fund Management (Switzerland) AG held a pre-capital increase shareholding of 4.35% of medmix' shares. For information on shareholders of medmix Ltd that have reported shareholdings of over 3% or a reduction of shareholdings below 3%, please refer to the website of the Disclosure Office of SIX Swiss Exchange ( For the positions held by medmix and information on shareholders, see note 21 to the consolidated financial statements. There are no cross-shareholdings where the capital or voting stakes on either side exceeds the threshold of 5%.